THRM Therma Bright

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

Toronto, Ontario--(Newsfile Corp. - June 24, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will test the SARS-CoV-2 (COVID-19) Delta variant, first detected in India, with its AcuVid™ antigen saliva test. Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall. The Delta variant has already become the dominant version of the SARS-CoV-2 (COVID-19) virus in the United Kingdom and has been detected in at least 74 other countries worldwide,

In addition, the Company has received the final 7 outstanding RT-PCR test results from the Brazilian study to match against its AcuVid™ saliva test, exceeding the minimum requirements of 30 positive/30 negative results for its FDA Emergency Use Authorization (EUA) submission. The study results will also be used for ANVISA (Brazil) and INVIMA (Colombia) submissions, as well as to further support the CE approval received in April 2021.

"We are excited that our Brazilian clinical study has now met the minimum FDA-EUA requirements for our submission to secure serial testing approval," expressed Rob Fia, Therma Bright's CEO. "In addition, we're equally excited to begin testing our AcuVid™ COVID-19 Rapid Antigen Saliva Test with the Delta variant; as we have successfully tested other fast-moving SARS-CoV-2 variants, including the P.1 and P.2 variants originally detected in Brazil and the B1.1.17 variant first detected in the UK. As always, our goal is to make our 15-minute AcuVid™ COVID-19 antigen test the leading rapid screening solution to help mitigate community spread of this virus."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

About Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Therma Bright Inc. trades on the (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX). For more information visit: and

For further information, please contact:

Therma Bright Inc.
Rob Fia, CEO

Follow us on .

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation, regulatory applications and manufacturing scale up as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit

EN
24/06/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Therma Bright

 PRESS RELEASE

EQS-News: Venowave VW5 von Therma Bright sichert sich den permanenten ...

EQS-News: Therma Bright Inc. / Schlagwort(e): Miscellaneous Venowave VW5 von Therma Bright sichert sich den permanenten HCPCS Code E0683 der Centers for Medicare & Medicaid Services des U.S.-amerikanischen Gesundheitsministeriums 20.08.2024 / 21:33 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Das Unternehmen wird voraussichtlich in der kommenden Woche ein Update zum Vertrieb in den USA gebenToronto, Ontario--(Newsfile Corp. - Dienstag, 20. August 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" oder das ...

 PRESS RELEASE

Venowave VW5 von Therma Bright sichert sich den permanenten HCPCS Code...

Das Gerät erhält als erstes medizinische Gebrauchsgerät seiner Art eine neue Bezeichnung der HCPCS-Stufe IIDas Unternehmen wird voraussichtlich in der kommenden Woche ein Update zum Vertrieb in den USA gebenToronto, Ontario--(Newsfile Corp. - Dienstag, 20. August 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" oder das "Unternehmen"), ein Entwickler und Investitionspartner für eine breite Palette führender, proprietärer Diagnostik- und Medizingerätetechnologien, freut sich bekannt zu geben, dass sein Venowave VW5 am 16. August 2024 von den Centers for Medicare and M...

 PRESS RELEASE

EQS-News: Therma Bright investiert in die entwicklung neuartiger behan...

EQS-News: Therma Bright Inc. / Schlagwort(e): Miscellaneous Therma Bright investiert in die entwicklung neuartiger behandlungen für COVID-19, asthma und chronisch obstruktive lungenerkrankung (COPD) 02.12.2022 / 23:52 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Toronto, Ontario--(Newsfile Corp. - Freitag, 2. Dezember 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" oder das "Unternehmen"), Entwickler eines intelligenten AcuVid™ COVID-19 Antigen-Speichel-Schnelltests und anderer fortschrittlicher Diagnose- und Medi...

 PRESS RELEASE

Therma Bright investiert in die entwicklung neuartiger behandlungen fü...

Toronto, Ontario--(Newsfile Corp. - Freitag, 2. Dezember 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" oder das "Unternehmen"), Entwickler eines intelligenten AcuVid™ COVID-19 Antigen-Speichel-Schnelltests und anderer fortschrittlicher Diagnose- und Medizingerätetechnologien, freut sich, den Abschluss einer Übernahmevereinbarung bekannt zu geben. Dabei geht es um einen Anteilserwerb an einer neuartigen Technologie für den Einsatz inhalierter Statine zur Behandlung von Atemwegserkrankungen wie Asthma, chronisch obstruktiver Lungenerkrankung ("COPD") und akuter entzündlicher L...

 PRESS RELEASE

Therma Bright Invests in the Development of Novel Treatments for COVID...

Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into an agreement to acquire an interest in a novel technology that utilizes inhaled statins for the treatment of respiratory conditions including asthma, chronic obstructive pulmonary disease ("COPD"), and acute lung inflammatory diseases including that caused by COVID-19 and other c...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch